|
|
Substance Name: Zonisamide [USAN:USP:INN:BAN:JAN]
RN: 68291-97-4
UNII: 459384H98V
InChIKey: UBQNRHZMVUUOMG-UHFFFAOYSA-N
Note
- A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
Molecular Formula
- C8-H8-N2-O3-S
Molecular Weight
- 212.2282
Classification Codes
- Anticonvulsant
- Anticonvulsants
- Antioxidants
- Calcium Channel Blockers
- Calcium-Regulating Hormones and Agents
- Cardiovascular Agents
- Central Nervous System Agents
- Drug / Therapeutic Agent
- Membrane Transport Modulators
- Protective Agents
- Reproductive Effect
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Zonisamide
- Zonisamide [USAN:USP:INN:BAN:JAN]
MeSH Heading
- Zonisamide
Synonyms
- 3-(Sulfamoylmethyl)-1,2-benzisoxazole
- AD-810
- BRN 1077076
- CI-912
- Exceglan
- Excegram
- HSDB 7293
- PD 110843
- PD-110843
- UNII-459384H98V
- Zonegran
- Zonisamida
- Zonisamida [Spanish]
- Zonisamide
- Zonisamidum
- Zonisamidum [Latin]
Systematic Name
- 1,2-Benzisoxazole-3-methanesulfonamide
Registry Numbers
CAS Registry Number
- 68291-97-4
FDA UNII
- 459384H98V
System Generated Number
- 0068291974
Structure Descriptors
InChI
InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)InChIKey
UBQNRHZMVUUOMG-UHFFFAOYSA-NSmiles
NS(=O)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | oral | 1gm/kg (1000mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING BEHAVIORAL: ATAXIA BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4337, 1987. |
monkey | LD50 | oral | > 1gm/kg (1000mg/kg) | BEHAVIORAL: ATAXIA AUTONOMIC NERVOUS SYSTEM: "SMOOTH MUSCLE RELAXANT (MECHANISM UNDEFINED, SPASMOLYTIC)" GASTROINTESTINAL: NAUSEA OR VOMITING | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4337, 1987. |
mouse | LD50 | intraperitoneal | 699mg/kg (699mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 477, 1980. | |
mouse | LD50 | intravenous | 816mg/kg (816mg/kg) | Drugs in Japan Vol. -, Pg. 600, 1990. | |
mouse | LD50 | oral | 1829mg/kg (1829mg/kg) | United States Patent Document. Vol. #4172896, | |
mouse | LD50 | subcutaneous | 1009mg/kg (1009mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4337, 1987. |
rat | LD50 | intraperitoneal | 733mg/kg (733mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 477, 1980. | |
rat | LD50 | intravenous | 672mg/kg (672mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4337, 1987. |
rat | LD50 | oral | 1992mg/kg (1992mg/kg) | BEHAVIORAL: ATAXIA BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4337, 1987. |
rat | LD50 | subcutaneous | 925mg/kg (925mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: ATAXIA BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4337, 1987. |